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Menispermi Rhizoma (MR), a well known traditional Chinese medicine, is widely used to
prevent and treat sore throat, enteritis, dysentery and rheumatoid arthralgia clinically.
However, many rhizomes of Chinese herbal medicines are mistaken as MR due to their
similar appearance, which could affect MR quality and cause serious consequences for
patients. To guarantee the quality of MR products, an ultra-high-performance liquid
chromatographyediode array detectoretandem mass spectrometry (UPLC-DAD-MS)
method was established for the characterization of major active ingredients in MR and its
preparations. By comparing their retention times and characteristic fragmentations with
those of authentic compounds, nine alkaloids in MR were unequivocally identified as
acutumidine, acutumine, magnoflorine, menisperine, dauricine, menisporphine, N-
demethyl-N-formyldehydronuciferine, 6-O-demethylmenisporphine and dauriporphine.
Quantitative analysis of the nine alkaloids in MR and its preparations was accomplished by
UPLC-DAD. A UPLC C18 column was employed for the chromatographic separation which
was effected by a gradient elution with acetonitrile and 0.1% aqueous formic acid solution
containing 5 mM ammonium acetate at a flow rate of 0.3 mL/min. This quantitative
method was validated with good linearity (R2  0.9991), desirable intra- and inter-day
precisions (RSD  3.32%), and acceptable recoveries (97.90e106.8%). The method was also
successfully applied to quantify nine alkaloids in eight batches of MR, six batches of MR
capsules and two batches of MR pills. A counterfeit MR sample from Henan province was
identified by the validated method, followed by further verification by appearance and
microscopic identification. The developed UPLC-DAD-MS method overcame the short-
comings of other quality control methods, such as scant chemical marker, long analytical
time, consumption of large amounts of organic solvents and limitation to MR or its single
dosage form.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
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j o u r n a l o f f o o d and d ru g an a l y s i s 2 1 ( 2 0 1 3 ) 2 0 6e2 1 8 2071. Introduction Medicine, Tianjin University of Traditional Chinese MedicineMenispermi Rhizoma (MR), the dried rhizome of Menis-
permum dauricum DC, with the function of clearing away
heat and toxic material, expelling wind and removing
dampness, is widely used to prevent and treat sore throat,
enteritis, dysentery and rheumatoid arthralgia clinically [1].
On account of facilitating clinical use, MR pills and capsules,
as two modern pharmaceutical dosage forms, have been
developed and recorded in the Chinese Pharmacopoeia [1].
Modern pharmacological studies have reported that alka-
loids are the major active ingredients in MR and its prepa-
rations [2], which have been demonstrated to have activities
of anti-inflammation [3], anti-bacterial [4], preventing
in vitro cancer cell proliferation [5], inhibiting platelet ag-
gregation [6], neuroprotection [7], and protecting against
myocardial ischemia and cerebral ischemia [8,9].
In recent years, many rhizomes of Chinese herbal medi-
cines such as Sophora tonkinensis Gagnep [10] and Aristolochia
mollissima Hance [11] have been mistaken for MR due to their
similar appearance, which could affect MR quality and cause
serious consequences for patients. To guarantee the quality of
MR and its preparations, several analytical methods have
been employed, such as high-performance liquid chroma-
tography with ultraviolet detector (HPLCeUV) [12,13], HPLC
with tandem mass spectrometry (HPLCeMS) [14], thin-layer
chromatography micellar fluorometry system [15], spectro-
photometric method [16], and capillary electrophoresis (CE)
[17]. However, these methods are confined by scant quanti-
tative markers [18], long analytical time, consumption of large
amounts of organic solvents and limitation to MR or its single
dosage form [13,19]. Thus, we were prompted to develop a
comprehensive analytical method to evaluate more bioactive
compounds in MR and its preparations to ensure their safety
and efficacy.
In this paper, an ultra performance liquid chromatography-
diode array detector-tandem mass spectrometry (UPLC-DAD-
MS) method was established for the characterization of alka-
loids in MR and its preparations. The validated UPLC-DAD
method was successfully applied to quantify nine alkaloids in
eight batches of MR purchased from different origins, six
batches of MR capsules and two batches of MR pills. A coun-
terfeit MR sample, identified using the validated method, was
further verified by appearance andmicroscopic identification.
Compared to previously reported methods, the newly devel-
oped analytical method was more comprehensive, selective,
sensitive and efficient for quality control of MR products.2. Methods
2.1. Materials
Eight batches of MR were obtained from various drug stores
throughout China and labeled as MD1e4 (Xinzhou, Shanxi,
China), MD5 (Taiyuan, Shanxi, China), MD6 (Zhengzhou,
Henan, China), MD7 (Nankai District, Tianjin, China) and
MD8 (Mongolia, China). All samples were authenticated by
Dr. Tianxiang Li from the College of Traditional Chinesein Tianjin, China. The voucher specimens were deposited in
the Tianjin State Key Laboratory of Modern Chinese Medi-
cine, Tianjin University of Traditional Chinese Medicine. Six
batches of MR capsules were collected from three pharma-
ceutical factories in China, which were labeled C-YC1-3, C-
JFK1-2 and C-WSLJ. Two batches of MR pills labeled P-AS and
P-YCWJS were purchased from two pharmaceutical factories
in China.
2.2. Chemicals and reagents
Reference standards, acutumidine, acutumine, magnoflorine,
menisperine, dauricine, menisporphine, N-demethyl-N-for-
myldehydronuciferine, 6-O-demethylmenisporphine and daur-
iporphine, were separated and purified from MR in our
laboratory, whose structures were elucidated by their spectra
data (MS, 1H NMR and 13C NMR). N-demethyl-N-formyldehy
dronuciferine was separated from this plant for the first time.
The purities of those standards were all above 97% using UPLC-
UV analysis. Their structures are shown in Fig. 1.
LC-grade water was obtained from a Milli-Q system (EMD
Millipore, Billerica, MA, USA). LC-grade acetonitrile and
methanol were purchased from Scharlau (Scharlab, S.L.,
Sentmenat, Spain). Formic acid and ammonium acetate were
supplied by DAMAO chemical reagent factory (Tianjin,
China).
2.3. Instrumentation and UPLC-DAD-MS analytical
conditions
Chromatographic separation was achieved on an Acquity
UPLC BEH C18 (2.1 100 mm, 1.7 mm) column by employing
theWaters Acquity UPLC system consisting of a column oven,
sample manager, binary solvent manager and DAD detector
(Waters Corp., Milford, MA, USA). The mobile phase was
composed of acetonitrile (A) and 0.1% formic acid aqueous
solution (B) using a gradient elution of 6e20% A in the first
11 minutes, 20e40% A during 11e16 minutes, 40e50% A dur-
ing 16e19 minutes, 50e52% A during 19e21 minutes, then a
linear increase to 90% A in the last minute. To attain better
resolution of the detected alkaloids, solution B was supple-
mented with 5 mM ammonium acetate. The column temper-
ature was fixed at 50 C and the flow rate was set at 0.3 mL/
min. Two different wavelengths were employed to monitor
and quantify the targeted compounds: 254 nm for acutumi-
dine, acutumine, menisporphine, N-demethyl-N-for-
myldehydronuciferine, 6-O-demethylmenisporphine and
dauriporphine; 282 nm for magnoflorine, menisperine and
dauricine. The injection volume was 2 mL.
A Waters Quattro Premier XE triple quadrupole mass
spectrometer (Waters Corp.) equipped with an electrospray
ionization (ESI) source was used for the identification of al-
kaloids in MR. The mass spectrometer was operated in posi-
tive ionizationmode. Themass spectrometric conditionswere
optimized as follows: cone gas (nitrogen) flow rate, 50 L/h;
desolvation gas (nitrogen) flow rate, 600 L/h; capillary voltage,
3200 V; source temperature, 120 C; desolvation temperature,
350 C; cone voltage, 30 V; collision activation dissociation gas
Fig. 1 e Chemical structures of the nine alkaloids in Menispermi Rhizoma.
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z 50e950 for full-scan MS analysis.
2.4. Preparation of standard solutions
Stock solutions were prepared by dissolving the accurately
weighed reference standards individually in methanolFig. 2 e Chromatograms acquired using different mobile phase
aqueous solution without ammonium acetate; (B) containing 5
acetate; (D) containing 15 mM ammonium acetate with a gradiecontaining a smaller part of dimethyl sulfoxide. A certain
amount of stock solution was then mixed to obtain the com-
bined solution at a concentration of 25.75 mg/mL for acutu-
midine, 5.130 mg/mL for acutumine, 354.5 mg/mL for
magnoflorine, 234.7 mg/mL for menisperine, 168.5 mg/mL for
dauricine, 1.760 mg/mL for menisporphine, 0.709 mg/mL for N-
demethyl-N-formyldehydronuciferine, 1.655 mg/mL for 6-O-systems included: (A) acetonitrile and 0.1% formic acid
mM ammonium acetate; (C) containing 10 mM ammonium
nt elution.
Table 1 e Results of methodological validation of the nine marker compounds.
Peak
no.
Compound Regression
equation
(n¼ 3)
r2 Linear
range
(mg/mL)
LOQ
(mg/mL)
Intra-day
(RSD%,
n¼ 6)
Inter-day
(RSD%,
n¼ 3)
Repeatability
(n¼ 6)
Stability
RSD%
Recovery (n¼ 6)
Mean
(mg/g)
RSD% Spiked
amount
(mg)
Recovery
(%)
RSD
%
1 Acutumidine Y¼ 20901X
9917.6
0.9991 0.800e25.75 0.040 0.17 0.85 1.190 1.50 0.52 0.1030 97.91 1.63
2 Acutumine Y¼ 20326X
330.44
0.9999 0.160e5.130 0.032 0.42 1.14 0.180 0.88 0.25 0.0181 99.64 2.37
3 Magnoflorine Y¼ 6782Xþ
2524.8
0.9999 2.216e354.5 0.111 0.19 0.60 17.42 0.89 0.55 1.1460 106.8 3.44
4 Menisperine Y¼ 8725Xþ
1753.3
0.9999 1.467e234.7 0.073 0.25 0.52 11.03 0.86 0.46 1.0521 101.1 3.46
5 Dauricine Y¼ 4518X
15543.0
0.9999 5.260e168.5 0.526 0.24 0.84 5.950 0.85 0.62 0.5776 97.90 1.33
6 Menisporphine Y¼ 54739Xþ
261.64
0.9999 0.055e1.760 0.011 1.95 3.32 0.078 2.28 1.77 0.0077 98.24 1.44
7 N-demethyl-
N-formyldehy-
dronuciferine
Y¼ 65110Xþ
303.69
0.9999 0.022e0.709 0.011 1.01 0.31 0.018 0.58 0.49 0.0018 101.9 1.20
8 6-O-
demethyl-
menisporphine
Y¼ 43622Xþ
47.025
0.9999 0.052e1.655 0.010 0.53 0.58 0.074 2.56 0.80 0.0066 103.1 1.35
9 Dauriporphine Y¼ 36429Xþ
128.63
0.9999 0.031e0.996 0.016 0.24 0.30 0.051 2.33 1.00 0.0053 103.4 1.42
LOQ¼ limit of quantification; RSD¼ relative standard deviation.
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Table 2 e Characterization of the nine alkaloids in Menispermi Rhizoma.
Peak
no.
TR
(min)
Positive ions (m/z) Identification
[MþH]þ CE (eV) MS2
1 2.04 384 20 367 [MþH-NH3]þ (6), 352 [MþH-CH3OH]þ (30), 348 [MþH-HCl]þ (24), 341
[MþH-NHCH2CH2]þ (100), 323[MþH-NHCH2CH2-H2O]þ (15), 316
[MþH-HCl-CH3OH]þ (16), 309[MþH-NHCH2CH2-CH3OH]þ (18), 305
[MþH-NHCH2CH2-HCl]þ (65), 299[MþH-HCl-CH3OH-NH3]þ (33), 291
[MþH-NHCH2CH2-H2O-CH3OH]þ (25), 287[MþH-NHCH2CH2-HCl-H2O]þ
(30), 273[MþH-NHCH2CH2-CH3OH-HCl]þ (38), 255[MþH-NHCH2
CH2-CH3OH-HCl-H2O]
þ (20)
Acutumidine
2 2.56 398 20 367[MþH-NH2CH3]þ (5), 362[MþH-HCl]þ (15), 341[MþH-NCH2CH2CH3]þ
(87), 323[MþH-NCH2CH2CH3-H2O]þ (14), 309[MþH-NCH2CH2CH3-CH3OH]þ
(8), 305[MþH-NCH2CH2CH3-HCl]þ (45), 273[MþH-NCH2CH2CH3-CH3OH-HCl]þ
(25), 58b [MþH-341]þ (100)
Acutumine
3 4.24 342a 30 299[M-NCH2CH3]
þ (6), 297[M-NHCH3CH3]
þ (43), 282[M-NHCH3CH3-CH3]
þ
(25), 267[M-NCH2CH3-CH3OH]
þ (7), 265[M-NHCH3CH3-CH3OH]
þ (60),
237[M-NCH2CH3-CH3OH-CH2O]
þ (17), 219[M-NCH2CH3-CH3OH-CH2O-H2O]
þ
(8), 58c [M-284]þ (100)
Magnoflorine
4 5.56 356a 30 313[M-NCH2CH3]
þ (5), 311[M-NHCH3CH3]
þ (15), 296[M-NHCH3CH3-CH3]
þ
(26), 281[M-NCH2CH3-CH3OH]
þ (23), 279[M-NHCH3CH3-CH3OH]
þ (87),
265[M-NHCH3CH3-CH3OCH3]
þ (15), 264[M-NHCH3CH3-CH3OH-CH3]
þ (45),
251[M-NCH2CH3-CH3OH-CH2O]
þ (20), 236[M-NCH2CH3-CH3OH-CH2O-CH3]
þ
(18), 58c [M-298]þ (100)
Menisperine
5 8.19 625 40 594[MþH-NH2CH3]þ (15), 582[MþH-NCH2CH3]þ (12), 563[MþH-2NH2CH3]þ
(3), 206d [MþH-419]þ (100)
Dauricine
6 19.15 322 30 294[MþH-CO]þ (5), 293 (100), 292[MþH-CH2O]þ (35), 279[MþH-CO-CH3]þ (5),
262[MþH-CO-CH3OH]þ (23), 250[MþH-CO-CH3CHO]þ (18)
Menisporphine
7 19.46 308 30 293[MþH-CH3]þ (18), 280[MþH-CO]þ (8), 278[MþH-CH2O]þ (14), 265
[MþH-CO-CH3]þ (30), 250[MþH-CO-CH2O]þ (10), 249[MþH-CH2O-NHCH2]þ
(100), 248[MþH-CO-CH3-NH3]þ (35)
N-demethyl-N-formylde-
hydronuciferine
8 21.04 308 30 293[MþH-CH3]þ (10), 290[MþH-H2O]þ (13), 280[MþH-CO]þ (8), 265
[MþH-CH3-CO]þ (100), 262[MþH-H2O-CO]þ (8), 236[MþH-C3H4O2e]þ (15)
6-O-demethylmenisporphine
9 21.25 352 30 322[MþH-CH2O]þ (95), 320[MþH-CH3OH]þ (8), 308[MþH-CH3CHO]þ
(100), 294[MþH-CH2O-CO]þ (22)
Dauriporphine
CE¼ collision energy.
a Mþ.
b m/z 58¼ N
+H.
c m/z 58¼ N .
d m/z 206¼
N+ OCH3
OCH3
.
e C3H4O2¼HOeC^CeOCH3.
Fig. 3 e UPLC-ESI-MS total ion current chromatogram in the positive ion mode of Menispermi Rhizoma. 1[ acutumidine;
2[ acutumine; 3[magnoflorine; 4[menisperine; 5[ dauricine; 6[menisporphine; 7[N-demethyl-N-
formyldehydronuciferine; 8[ 6-O-demethylmenisporphine; 9[ dauriporphine.
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The combined solutionswere further diluted to give a series of
concentrations for linear validation.2.5. Preparation of sample solutions
Thedried rhizomeofMenispermumdauricumDCwaspulverized
into a fine herb powder (100 mesh). The MR pills and contents
of the MR capsules were ground into preparation powder
(100 mesh). Then, 200 mg of herb powder or 50 mg of prepa-
ration powder was accurately weighed and extracted with
20 mL of 75%methanol in an ultrasonic bath for 40 minutes at
room temperature. Additional 75% methanol was added to
makeup the lostweight.Next, 1 mLof the sample solutionwasFig. 4 e The MS2 spectra and fragmentation patterns of acutum
formyldehydronuciferine and dauriporphine.diluted to 2 mL with 50%methanol. The solution was used for
UPLC analysis after centrifugation at 14,000g for 15 minutes.3. Results and discussion
3.1. Optimization of UPLC-DAD-MS conditions
To optimize UPLC conditions, preliminary experiments were
conducted to test the chromatographic column, column
temperature, flow rate and mobile phases. The Acquity UPLC
BEH C18 column (2.1 100 mm, 1.7 mm) was selected for
UPLC-DAD-MS analysis based on its good separation ability
and short analytical time. With the aim of obtainingidine, menisperine, dauricine, N-demethyl-N-
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shape, a small amount of ammonium acetate was added to
0.1% formic acid aqueous solution, which markedly
improved the separation effect of the investigated alkaloids
on the UPLC BEH C18 column. Various final concentrations
(5 mM, 10 mM, 15 mM) of ammonium acetate in 0.1% formic
acid aqueous solution were examined. The chromatograms
obtained (Fig. 2) indicated that the most satisfactory effect
was achieved when 5 mM ammonium acetate was added,
especially for the chromatographic separation of N-
demethyl-N-formyldehydronuciferine, menisporphine, 6-O-
demethylmenisporphine and dauriporphine.
Under these optimized MS conditions, the alkaloids gave
stronger signal responses in positive ion mode than negative
ion mode. To obtain higher sensitivity, the cone voltage and
capillary voltage were optimized to generate protonated
molecules of the analytes. The fragment energy was opti-
mized to achieve maximum response of the compound frag-
ment ion peaks.3.2. Optimization of sample preparation
According to the comparative results of different methods
for sample preparation, ultrasonic extraction wasdemonstrated to be simpler and more efficient than reflux
extraction. The crucial parameters, including ultrasonic
time (20, 30, 40 and 50 minutes), solvent for extracting (50%,
75% and 100% methanol), and the ratio of solvent to sample
weight (25, 50, 100 and 150 mL per gram of herbs), were then
optimized individually. The final conditions for sample
preparation were set as follows: 200 mg herb powder or
50 mg preparation powder extracted with 20 mL of 75%
methanol in an ultrasonic bath for 40 minutes at room
temperature.3.3. Methodological validation of determining nine
alkaloids by UPLC-DAD
Methodological validation for quantification of nine alka-
loids in MR and its preparations was carried out by UPLC-
DAD with regard to linearity, intra- and inter-day preci-
sion, limit of quantification, stability, repeatability and re-
covery. The linearity with a correlation coefficient value
above 0.9991 was approved for the nine alkaloids. The limit
of quantification of the tested compounds expressed as a
signal-to-noise ratio of 10:1 was in the range of
0.010e0.526 mg/mL. The appraisal of the intra- and inter-day
precision of this method was independently performed by
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ysis of samples in the consecutive 3 days, the relative
standard deviations (RSDs) of which were below 3.32%.
Repeatability was evaluated by six samples prepared in
parallel; the results were able to satisfy the quantitative
analysis of the nine alkaloids in the samples. The targeted
analytes were certified to be stable with RSD values below
1.77% by replicate analysis of one sample at 0, 2, 4, 8, 10 and
12 hours. The recoveries were investigated by adding
authentic standards to the sample, the amount of which
were generally equal to those contained in the sample. The
samples in sextuplet were prepared as mentioned above.
Satisfactory recoveries between 97.90% and 106.8% were
achieved, with RSD values less than 3.46%. The detailed re-
sults of methodological validation are listed in Table 1.
3.4. Identification and characterization of alkaloids in
MR and its preparations by UPLC-DAD-MS/MS
The UPLC-DAD-ESI-MS/MS method was employed to identify
and characterize major active ingredients in MR and its
preparations. Comparing retention times and MS character-
istic fragmentations with those of reference standards, nine
compounds were unambiguously identified as acutumidine,
acutumine, magnoflorine, menisperine, dauricine, menis-
porphine, N-demethyl-N-formyldehydronuciferine, 6-O-
demethylmenisporphine and dauriporphine in MR. Only six
alkaloids were detected in the MR preparation: acutumidine,
acutumine, magnoflorine, menisperine, dauricine and 6-O-
demethylmenisporphine. The total ion current chromato-
gram of MR is shown in Fig. 3. The retention time, protonated
molecules or molecular ions and fragmentation information
of the nine alkaloids are displayed in Table 2. According to
their chemical structures, the nine alkaloids can be classified
into five categories as follows: morphinane alkaloids (acutu-
midine and acutumine), aporphine quaternary ammonium
alkaloids (magnoflorine and menisperine), oxoisoaporphine
alkaloids (menisporphine, 6-O-demethylmenisporphine and
dauriporphine), dehydroaporphine alkaloids (N-demethyl-N-
formyldehydronuciferine), and bisbenzylisoquinoline alka-
loids (dauricine).
As shown in Fig. 4, the protonated molecule [MþH]þ of
acutumidine yielded three dominant fragment ions atm/z 367
[MþH-NH3]þ, 348 [MþH-HCl]þ and 341 [MþH-C2H5N]þ in (þ)
ESI-MS/MS, which could be attributed to the consecutive loss
of one NH3, one HCl and one NHCH2CH2. In (þ) ESI-MS/MS
spectrum, menisperine displayed the base peak at m/z 58
[M-298]þ, which embodied the characteristic cleavage of
aporphine quaternary ammonium alkaloids. In addition,
fragment ions atm/z 313 [M-C2H5N]
þ,m/z 311 [M-C2H7N]
þ and
m/z 279 [M-C2H7N-CH3OH]
þ were also observed. Dauricine, a
bisbenzylisoquinoline alkaloid, exhibited characteristic frag-
ment ionsatm/z 594 [MþH-CH5N]þ,m/z 582 [MþH-C2H5N]þ and
m/z 206 [MþH-419]þ. N-demethyl-N-formyldehydronuciferine
gave fragment ions at m/z 280 [MþH-CO]þ and m/z 278 [MþH-
CH2O]
þ, which indicated the neutral loss of CO and HCHO.
Different from other alkaloids, dauriporphine, as an oxoisoa-
porphine alkaloid that has relatively stable mother nucleus
structures, tended to give fragment ions at m/z 322 [MþH-
CH2O]
þ and m/z 320 [MþH-CH4O]þ, suggesting the loss of
Table 4 e Detailed descriptions of certified and counterfeit herbs.
Appearance Microscopic characteristics
Menispermi
Rhizoma (MD2)
Slim, cylindrical and branched, 0.3e0.8 cm in diameter.
Covered with brownish-yellow or dark brown cuticle outside,
which is easy to be flaked. Flexible texture, not easy to break,
irregular cross-section. Xylem is pale yellowish and
medullated [23].
Powder: pale brownish-yellow. Vessels bordered
pitted. Stone cells singly scattered. Crystals of
calcium oxalate minute and gritty centered in
tegumental cells and ray cells. Epidermal cells
are numerous. Cork consists of several layers
of cells. Wood fibers and phloem fibers bunchy
or scattered [23].
Counterfeit (MD6) Cylindrical and multi-branched, 0.5e1.5 cm in diameter.
Covered with light gray to reddish-brown cuticle outside.
Hard texture, not easy to break, relatively flat cross-section,
shows evident concentric rings and radial striation. Xylem
is pale yellowish.
Powder: pale brownish-yellow. Vessels reticulate
and bordered pitted, pale yellowish or golden
yellowish. Stone cells clumped or singly scattered.
Crystals of calcium oxalate square, rhombic or
irregularly shaped. Crystal fiber, xylem parenchyma
and cuticle masses are numerous. Non-glandular
hairs existent.
j o u r n a l o f f o o d and d ru g an a l y s i s 2 1 ( 2 0 1 3 ) 2 0 6e2 1 8 215formaldehyde andmethanol, respectively. Thesefive alkaloids
(acutumidine, menisperine, dauricine, N-demethyl-N-
formyldehydronuciferine and dauriporphine) possessing their
own characteristic fragmentation patterns were chosen as
typical examples, whose MS2 spectra and detailed fragmen-
tation patterns are displayed in Fig. 4 [20e22].3.5. Quantitative analysis of the nine alkaloids in MR
from different origins
The validated UPLC-DAD method was applied to simulta-
neous quantitative analysis of the nine alkaloids in MR
collected from different drug stores distributed in different
provinces in China.
From the analytical results listed in Table 3, it was found
that MD6 (Zhengzhou, Henan, China) was different from the
other samples in that most of the important alkaloids could
not be detected. Therefore, it was tentatively identified as a
counterfeit drug. To confirm our conjecture about MD6,
further appearance and microscopic identification were per-
formed. The detailed descriptions ofMR (MD2) and counterfeit
(MD6) are listed in Table 4 [23]. The pictures of microscopic
identification are shown in Fig. 5.
In another seven MR samples, the contents of the nine al-
kaloids varied greatly from 0.008 mg/g to 17.42 mg/g. Acutu-
midine, acutumine, magnoflorine, menisperine and dauricine
with retention time less than 8 minutes (16% acetonitrile in
mobile phase at 8 minutes) were considered to be readily sol-
uble in water, the contents of which were in the range of
0.17 mg/g to 17.42 mg/g. It may be deduced that these alkaloids
might be the major bioactive compounds in MR. Menispor-
phine, N-demethyl-N-formyldehydronuciferine, 6-O-deme-
thylmenisporphine and dauriporphine with retention time
more than 19minutes (50% acetonitrile at 19 minutes) were
considered as fat-soluble components, whose contents were
below 0.13 mg/g. The total contents of the nine alkaloids varied
from 24.05 mg/g to 36.05 mg/g. The discrepancies among the
samples of different origins were obvious. Accordingly, it is
necessary to pay close attention to the quality evaluation ofMR
in clinical use.3.6. Quantification of the nine alkaloids in MR
preparations from different pharmaceutical factories
The established analytical method was also employed to
determine the nine alkaloids in preparations manufactured
from MR, including six batches of capsules from three man-
ufacturers and two batches of pills from different pharma-
ceutical factories. Compared with the analytical results of MR,
the most obvious variation was that dauricine, as the chemi-
cal marker for MR preparation (capsules and pills) in the
Chinese Pharmacopoeia, had the highest content from
50.13 mg/g to 103.1 mg/g. The contents of the other four
water-soluble components (acutumidine, acutumine, mag-
noflorine and menisperine) were still relative high. As for the
four fat-soluble components, menisporphine, N-demethyl-
N-formyldehydronuciferine and dauriporphine with low
contents in MR could not be detected in any of these eight
preparations, while 6-O-demethylmenisporphine was assayed
with a content of 0.044e0.068 mg/g in the preparations. Ac-
cording to the Chinese Pharmacopoeia, MR preparations
(capsules and pills) are manufactured from standardized MR
extracts, which are obtained by acid-base treatment of MR
using dauricine as a chemical marker. Therefore, water-
soluble components are well reserved in MR preparations
(capsules and pills), especially for dauricine, while fat-soluble
components are not well transferred from the rawmaterial to
the standardized MR extracts.
The different batches of MR preparations from one manu-
facturer had a relatively stable content of targeted compounds.
However, the individual content of detected compounds varied
significantly inMR preparations with different dosage forms or
single dosage form from different manufacturers. This may be
due to the different manufacturing procedures and the
different weights of each unit (average weight for each unit:
0.30 0.0057 g forC-YC,0.20 0.0095 g forC-JFK, 0.18 0.0031 g
for C-WSLJ, 0.11 0.027 g for P-AS, 0.18 0.0035 g for P-YCWJS).
On account of regulations released by the Chinese Pharmaco-
poeia, the contentsof dauricine inMRpills and capsulesused in
our study must exceed 6 and 12mg per unit, respectively. The
analytical results indicated that all of the samples collected
from the differentmanufacturers fulfilled these standards. The
Fig. 5 e Pictures of microscopic identification. 1[Menispermi Rhizoma (MD2); 2[ counterfeit (MD6); A[ vessels; B[ stone
cells; C[ cork cells; D[ epidermal cells; E[ crystals of calcium oxalate; F[ starch granules; G[ phloem fiber; H[wood
fiber; I[ crystal fibers; J[non-glandular hair; K[horny block; L[ xylem parenchyma.
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 1 ( 2 0 1 3 ) 2 0 6e2 1 8216
Fig. 6 e UPLC-UV chromatograms of: (A) standard solution; (B) Menispermi Rhizoma; (C) Menispermi Rhizoma capsule;
(D) Menispermi Rhizoma pill. 1[ acutumidine; 2[ acutumine; 3[magnoflorine; 4[menisperine; 5[ dauricine;
6[menisporphine; 7[N-demethyl-N-formyldehydronuciferine; 8[ 6-O-demethylmenisporphine; 9[ dauriporphine.
j o u r n a l o f f o o d and d ru g an a l y s i s 2 1 ( 2 0 1 3 ) 2 0 6e2 1 8 217total contents of thealkaloids showedmarkeddiversities in the
eight samples from 67.62 mg/g to 119.72 mg/g.
This validated method was successfully applied to the
quality control of MR preparations including capsules and
pills, which provided particularly important information for
production and application. The UPLC-UV chromatograms of
the standard solution, MR, MR capsules and pills are shown in
Fig. 6.4. Conclusion
In our study, nine alkaloids in MR were ambiguously identified
and characterized by UPLC-DAD-MS, which were further
quantified by UPLC-DAD. The established method described
herein for the qualitative and quantitative analyses of the nine
alkaloids was successfully applied in MR, MR capsules and
pills; the method has also overcome the shortcomings of other
quality control methods, such as scant chemical marker, long
analytical time, consumption of large amounts of organic sol-
vents and limitation to MR or its single dosage form.
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